Publication | Open Access

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study

Thrombotic EventsThrombosisVenous ThrombosisCardiovascular DiseasePatient SafetyHematologyPharmacotherapyMedicineAnticoagulantPrevent-hd StudyEmergency MedicineCovid-19